Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A15447 | Pages: 171 | Charts: 55 | Tables: 115 |
The global hepatitis E diagnostic tests market size was valued at $61.7 million in 2021, and is projected to reach $93.5 million by 2031, growing at a CAGR of 4.2% from 2022 to 2031. Hepatitis E is a liver disease caused due to infection of hepatitis E virus (HEV). It includes inflammation to the liver along with some symptoms such as jaundice and nausea. The infection is usually transmitted through oral-fecal route, where drinking water contaminated with fecal residues remains the main cause of infection. In addition, vertical transmission that is from pregnant women to the baby, infected blood products used in medical treatments and intake of uncooked meat and meat products from hepatitis E infected animals are the major factors for the spread of infection.
[COVIDIMPACTSTATEMENT]
Get more information on this report : Request Sample Pages
Furthermore, hepatitis E presents is a hyper endemic disease in low-resource countries where there is poor sanitation which leads to fecal contamination of food and water supplies. Inappropriate sanitation in the underdeveloped and developing countries is also the main cause of this infection and these regions are the main targets for spread of diseases such as hepatitis E and others. This leads to rise in number of hepatitis infection cases, which further rises the demand for hepatitis E diagnostic test kits in this region.
Furthermore, hepatitis E can also lead to serious health threats to patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy, which results in severe liver disease and death of the patient. In addition, during epidemics, fulminant hepatitis E is witnessed on a large scale among pregnant women, which is typically most severe during the third trimester of pregnancy. According to World Health Organization, 20–25% of pregnant women are at high risk and may die if infected by hepatitis E in third trimester. This highlights the need for early diagnosis of this infection which rises the demand for hepatitis E diagnostic tests kits, and propels the growth of the hepatitis E diagnostic tests market size.
In addition, rise in prevalence of hepatitis E, rise in awareness about hepatitis E and its diagnosis among people, and rise R&D activities in the diagnostic field are the driving factors for the hepatitis E diagnostic tests market share. These drivers provide a favorable environments for increase in the sales of the products and also for the growth of the overall market. However, the market may be somewhat constrained throughout the anticipated period due to complications in handling the kits and limitation in its storage conditions.
Impact of COVID-19 Hepatitis E Diagnostic Tests Market
Coronavirus Severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. WHO declared COVID-19 as a pandemic on March 11, 2020, and by September 21, 2022, over 613 million people have been infected globally with over 65.3 lakhs deaths. COVID-19 symptoms include fever, cough, and shortness of breath.
The COVID-19 outbreak is anticipated to have a negative impact on growth of the global hepatitis E diagnostic tests market. A survey was carried out by the World Hepatitis Alliance (WHA), a network of more than 300 community-based organizations across 100 countries in March–April, 2020. According to the survey, there was interruptions in the services, along with delays in implementing major programs regarding the hepatitis diagnosis and management. Moreover, the COVID-19 pandemic has affected the hepatitis prevention, testing, treatment, and vaccination services around the globe, which further lead to a negative impact on the hepatitis E diagnostic test market.
In addition, the COVID-19 have also imperiled the national elimination plan for viral hepatitis owing to diverted resources and attention of the healthcare sector. Furthermore, the government funding in hepatitis cases reduced due to COVID- 19 funding, which further reduced the patients opting for diagnosis and treatment of hepatitis E. In addition, decrease in the patient visit to the hospitals reduced during the pandemic, which further negatively affected the hepatitis E diagnostic tests market growth.
However, regularization of supply chain of medications and medical devices by key players and rise in the number of patient visits for investigation and treatment post pandemic is anticipated to fuel the growth of market after COVID-19 pandemic.
The hepatitis E diagnostic tests market is segmented on the basis of test type, by end user and region. On the basis of test type, it is divided into ELISA HEV IgM test, ELISA HEV IgG test, and RT-PCR test. On the basis of end user, the market is segmented into hospitals, diagnostic centers, and others.
On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
On the basis of test type, the HEV IgM ELISA Test segment registered the largest revenue for the year 2021, and is expected to grow at a highest CAGR during the hepatitis E diagnostic tests market forecast period owing to the rise in the investment by the key market players to manufacture the HEV IgM ELISA Test and others associated products to meet the rising demand of the healthcare sector.
[TESTTYPEGRAPH]
On the basis of end user, the diagnostic centers segment held the largest share of the hepatitis E diagnostic tests market in 2021 and is expected to grow at the highest CAGR during the forecast period, which is mainly rise in number of diagnostic centers around the globe due to the rise in demand for diagnostic services during the COVID-19 pandemic.
[ENDUSERGRAPH]
On the basis of region, Asia-Pacific acquired a major share in 2021, and is expected to witness the highest rate of CAGR for the hepatitis E diagnostic tests market during the forecast period owing to prevalence of various infectious diseases in this region. This, leads to rise in sale of diagnostic kits and increase the revenue share of this region.
[REGIONGRAPH]
Some of the major companies that operate in the global hepatitis E diagnostic tests industry are Altona Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd, Dia.Pro Diagnostic Bioprobes s.r.l, ELITechGroup, F. Hoffmann-La Roche Ltd., Fortress Diagnostics, Mikrogen Diagnostik, MP Biomedicals, PerkinElmer, Inc. (EUROIMMUN Medizinische Labordiagnostika AG) and Primerdesign Ltd.
Key Market Segments
Key Market Players